Clinical Trial Update: Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating US-ATG-F to prevent chronic graft-versus-host disease in hematologic malignancy patients has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Graft-versus-host Disease
• Myelodysplastic Syndrome

Drugs mentioned

• US-ATG-F (antithymocyte globulin-F)

Snippet

Sponsor: Neovii Biotech | Conditions: GVHD, Adult Acute Myeloid Leukemia | Phase 3 | Status: COMPLETED | Results posted: 2019-03-20